(Eagle News) — Drug manufacturer Sanofi Pasteur on Monday reiterated it would not refund the Philippine government the P3 billion it used to purchase the anti-dengue vaccine Dengvaxia.
Sanofi also said it would not set up an indemnification fund as requested by the Department of Health.
According to the French company, the “Dengvaxia vaccination in the Philippines will provide a net reduction in dengue disease, including severe dengue.”
Dengvaxia, “like all other vaccines, has never claimed 100% efficacy in its approved label,” the company said.
It added it continued to empathize with “any and all individuals and families that have been affected by these difficult circumstances,” noting that it was also ready to sit down with the DOH to help it fight degue and help it restore the public’s trust in vaccination programs.
